Literature DB >> 29636064

Traditional Chinese and western medicine for the prevention of deep venous thrombosis after lower extremity orthopedic surgery: a meta-analysis of randomized controlled trials.

Shibai Zhu1, Yi Song2, Xi Chen1, Wenwei Qian3.   

Abstract

BACKGROUND: Chinese herbal medicine has traditionally been considered to promote blood circulation to remove obstruction in the channels and clear pathogenic heat to drain dampness effects. We conducted this meta-analysis to evaluate its benefits for the prevention of deep venous thrombosis (DVT) after lower extremity orthopedic surgery.
METHODS: Relevant, published studies were identified using the following keywords: lower extremity orthopedic surgery, arthroplasty, joint replacement, fracture, traditional Chinese and western medicine, Chinese herbal medicine, deep venous thrombosis (DVT), and Venous thromboembolism (VTE). The following databases were used to identify the literature consisting of RCTs with a date of search of 31 May 2017: PubMed, Cochrane Library, Web of knowledge, the Chinese National Knowledge Infrastructure Database, the Chongqing VIP Database, the Chinese Biomedical Database, and the Wanfang Database (including three English and four Chinese databases). All relevant data were collected from studies meeting the inclusion criteria. The outcome variables were the incidence rate of DVT, activated partial thromboplastin time (APTT), prothrombin time (PT), and D-dimer; subcutaneous hematoma; and other reported outcomes. RevMan5.2. software was adopted for the meta-analysis.
RESULTS: A total of 20 published studies (1862 cases) met the inclusion criteria. The experimental group, 910 patients (48.87%), received the Chinese herbal medicine or traditional Chinese and western medicine for prevention of DVT; the control group, 952 patients (51.13%), received the standard western treatment. The meta-analysis showed that traditional Chinese and western medicine therapy reduced the incidence rates of DVT significantly when compared with controls (risk ratio [RR] = 0.40; 95% CI, 0.30 to 0.54; P < 0.00001), and the D-dimer was lower in the experimental group (P = 0.01). Besides, the incidence rate of subcutaneous hematoma was lower in the experimental group (P < 0.0001). However, no significant difference was found in the PT (P = 0.98) and APTT (P = 0.75) in two groups. No serious adverse events were reported.
CONCLUSION: Traditional Chinese and western medicine therapy may be a safe, effective prevention modality for DVT after lower extremity orthopedic surgery. Further rigorously designed, randomized trials are warranted.

Entities:  

Keywords:  Deep venous thrombosis (DVT); Lower extremity orthopedic surgery; Meta-analysis; Traditional Chinese and western medicine

Mesh:

Substances:

Year:  2018        PMID: 29636064      PMCID: PMC5894226          DOI: 10.1186/s13018-018-0785-2

Source DB:  PubMed          Journal:  J Orthop Surg Res        ISSN: 1749-799X            Impact factor:   2.359


  9 in total

1.  Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Catherine Curley; Ola E Dahl; Sam Schulman; Thomas L Ortel; Stephen G Pauker; Clifford W Colwell
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.

Authors:  Joshua J Jacobs; Michael A Mont; Kevin John Bozic; Craig J Della Valle; Stuart Barry Goodman; Courtland G Lewis; Adolph Chick J Yates; Lisa N Boggio; William C Watters; Charles M Turkelson; Janet L Wies; Patrick Sluka; Kristin Hitchcock
Journal:  J Bone Joint Surg Am       Date:  2012-04-18       Impact factor: 5.284

3.  [Clinical research on Sanmiao powder combined fibrinogenase for injection in treatment of acute deep venous thrombosis of lower limbs].

Authors:  Tao Zhou; Da-Qing Sun; Peng Wu
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2012-07

4.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

5.  Best practice guidelines for Australia and New Zealand on the prevention of venous thromboembolism: issues and implications for nurses.

Authors:  Jessica Schluter; Hayden Scotter; Wendy Chaboyer
Journal:  Contemp Nurse       Date:  2008-05       Impact factor: 1.787

6.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Authors:  Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins
Journal:  BMJ       Date:  2011-07-22

7.  Korean guidelines for the prevention of venous thromboembolism.

Authors:  Soo-Mee Bang; Moon Ju Jang; Doyeun Oh; Yeo-Kyeoung Kim; In Ho Kim; Sung-Soo Yoon; Hwi-Joong Yoon; Chul-Soo Kim; Seonyang Park
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

8.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  [Chinese drugs for supplementing Qi and activating blood circulation in preventing deep venous thrombosis after big operations in orthopaedics and traumatology].

Authors:  Chunqiang Bi; Jianmin Wen; Kewei Jiang; Si Chen; Chaolu Wang; Weidong Sun; Yongsheng Sun; Zhao Liang; Yongzhong Cheng; Ting Cheng; Haiwei Hu
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2009-03
  9 in total
  6 in total

Review 1.  Xueshuantong Injection in Treating Deep Venous Thrombosis: A Systematic Review and Trial Sequential Analysis.

Authors:  Wenhui Li; Feng Xu; Renyan Huang; Weijing Fan; Changgeng Fu; Lei Xu; Xvhong Wang; Huimin Lu; Yuanxiang Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-07       Impact factor: 2.629

Review 2.  Traditional Chinese Medicine for Postoperative Care following Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-Analysis.

Authors:  Hokyung Chang; Hyungsuk Kim; Koh-Woon Kim; Jae-Heung Cho; Mi-Yeon Song; Won-Seok Chung
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-20       Impact factor: 2.629

3.  Taohong Siwu-Containing Serum Enhances Angiogenesis in Rat Aortic Endothelial Cells by Regulating the VHL/HIF-1α/VEGF Signaling Pathway.

Authors:  Zhi Tang; Wangyang Li; Hongzan Xie; Shengping Jiang; Yunqing Pu; Hui Xiong
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-22       Impact factor: 2.629

4.  Prediction Models for Prognosis of Femoral Neck-Fracture Patients 6 Months after Total Hip Arthroplasty.

Authors:  Xiaofeng Zheng; Cong Xiao; Zhuocheng Xie; Lijuan Liu; Yinhua Chen
Journal:  Int J Gen Med       Date:  2022-04-21

5.  Combination of Traditional Chinese Medicine and Low-Molecular-Weight Heparin Prevents Deep Vein Thrombosis After Surgery: A Meta-Analysis.

Authors:  Chu Chen; Qing Tang; Wenjuan Zhang; Huijun Yuan; Ying Huai; Kai Jiang; Yilun Wu; Heping Zhao
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

6.  Implementation of Enhanced Recovery After Surgery (ERAS) protocol for elderly patients receiving surgery for intertrochanteric fracture: a propensity score-matched analysis.

Authors:  Wenhao Zhu; Yinjie Yan; Yijin Sun; Zhaoxiang Fan; Niangkang Fang; Yunlu Zhang; Mengchen Yin; Hongbo Wan; Wen Mo; Wei Lu; Xuequn Wu
Journal:  J Orthop Surg Res       Date:  2021-07-28       Impact factor: 2.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.